Chloroquine as an anti-autophagy drug in small cell lung cancer (SCLC) patients: A phase I trial to be followed by a phase II trial.

To determine the toxicity of adding chloroquine in escalating doses in SCLC patients: to standard dose cisplatin-etoposide in extensive disease SCLC = STEP 1, and - to standard dose concurrent radiotherapy and cisplatin-etoposide in limited disease SCLC = STEP2